anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Apparatus and associated methods relate to providing secure gatekeeping of a communication transmitted from an implantable biomedical device to a remote internet-based website. A gatekeeping device wirelessly receives the communication transmitted from the implantable biomedical device. The communication wirelessly received is encoded by the implantable biomedical device using a first encoding algorithm. The gatekeeping device then decodes the communication wirelessly received. The gatekeeping device then encodes the communication decoded using a second encoding algorithm. The gatekeeping device relays the communication encoded using the second encoding algorithm to the remote internet-based website via the internet. In some embodiments, the gatekeeping device transmits a proximity signal to be used to determine proximity of the gatekeeping device to the implantable biomedical device.
The invention belongs to the biotechnology field, and particularly relates to a hyperlipidemia preventing and treating microecological preparation and a preparation method and application thereof. The preparation composition comprises natto dehydro freezing powder, probiotics and medicinal and edible traditional Chinese medicine, and particularly comprises, by weight, 20-40 parts of the natto dehydro freezing powder, 15-40 parts of hawthorn fruits, 18-35 parts of gingkoes and 5-25 parts of lentinula edodes. One or more kinds of lactobacillus plantarum, Lactobacillus reuteri and bifidobacterium adolescentis are adopted as the probiotics. The viable count of probiotics in per g composition is larger than or equal to 1*109 cfu. The preparation method is easy, operation is simple and industrial production is easy to realize. Experiments verify that the obtained probiotics traditional Chinese medicine preparation has the prevention and adjuvant treatment effect on hyperlipidemia, can adjust intestinal flora balance while preventing hyperlipidemi, can improve immunity, is safe and long in service life, can be made into powder, tablets, capsules and the like, and has the wide application prospect.
After a first episode of acute deep venous thrombosis (DVT) the risk of recurrence is relatively high and clinical consequences are important. Therefore, secondary prophylaxis using oral anticoagulant treatment (OAT) is usually established in these patients. This treatment very effectively reduces the risk of recurrences but induces an increased risk of bleeding. Major bleeding complications can be expected in \~2% patient-years. Therefore, current recommendations limit OAT to a period of 3 to 12 months. After stopping of OAT, however, \~10 % of patients with an initial episode of unprovoked DVT will develop a recurrent event within 1 year. This group of patients may benefit from prolonged OAT. The results of 2 independent observational studies showed a significantly higher risk of recurrence in patients showing increased levels of D-Dimer after withdrawal of OAT. D-Dimer is a biomarker that indicates fibrin formation followed by fibrinolysis. Based on these data we hypothesize that D-Dimer testing can be successfully used to tailor the duration of OAT in patients after an unprovoked episode of DVT. This clinical trial will investigate this hypothesis using a prospective, randomized, and controlled design.
Participants in the control group will receive usual care from their healthcare team (if relevant) and will be invited to have an assessment at baseline and 6-weeks. Control participants will not receive any form of intervention. At the end of the study, control participants will receive a summary of their physical activity data measured at baseline and 6-weeks (in a booklet format with guidance on how to interpret and use the information).
32 healthy volunteers will be separated into four groups: 8 young lean men, 8 young obese men, 8 aged lean men and 8 aged obese men. They will come to the center four times after inclusion, with 2 to 4 weeks wash out each time. At the first visit they will undergo different test to evaluate their body composition, glucose tolerance, resting energy expenditure, and muscular strength. At the other three visits, people will undergo a kinetic blood sampling, urine and biopsies of adipose tissue over a period of 8h after ingestion of a test meal. The different meals tested (Oleic acid vs palmitic acid vs no lipid) will be given in a random way over the three visits. Before each of these three visits, a controlled diet will be established. At the last visit body composition and muscular strength will be evaluated.
If randomized to the 12-month Fun First program, participants will attend weekly interactive small-group sessions led by health coaches for 6 months, then receive monthly phone calls from coaches for 6 months. The first 6 months consists of a 2-month module promoting enjoyment of key maintenance skills before losing weight, followed by a 4-month behavioral weight-loss program.
Patients had a lead-in period of 16 weeks before baseline, pegifn α- 2b single drug treatment for 24 weeks, 4 weeks after drug withdrawal, 16 weeks of introduction period, pegifn α- 2b was followed up for 24 weeks. The plan of the induction period is as follows: 1) from the first day of the induction period, GM-CSF is injected subcutaneously ® one hundred μg/ piece, produced by Xiamen Tebao Bioengineering Co., Ltd.), 100 μg/ day, 5 consecutive days, one cycle every 4 weeks, 4 consecutive cycles. 2) On the third day of the induction period, recombinant hepatitis B vaccine (Saccharomyces cerevisiae) (1.0ml/HBsAg 60 per dose) was injected subcutaneously μg. Shenzhen Kangtai Biological Products Co., Ltd.), 60 μ g. Once every 4 weeks for 4 consecutive cycles, the course of treatment was 68 weeks, and the patients were followed up for 24 weeks.
The present invention relates to a composition for preventing and treating obesity and hyperlipidemia, containing Curcuma longa and Dendropanax morbifera LEV. as an active ingredient. More specifically, provided is a composition composed of 30-40% of roots and stems of Curcuma longa, 30-40% of burdock roots, 10-20% of onion, and 5-15% of Dendropanax morbifera LEV. The composition of the present invention exhibits synergistic weight reducing effects in vivo. The composition also exhibits total cholesterol inhibitory effects and also influences on hyperlipidemia. Thus, the composition of the present invention can be useful as a pharmaceutical composition or a functional health food for preventing or treating obesity or arteriosclerotic vascular disease including hypercholesterinemia.
The prevalence of morbid obesity is increasing worldwide. As the severity of obesity increases, the incidence of diagnosed obstructive sleep apnea also rises. Studies have shown an incidence of sleep apnea as high as 64% in patients with a body mass index (BMI) over 40 and 100% in patients with a BMI greater than 60. Patients with OSA have been shown to have significant desaturations under intravenous sedation due to airway narrowing and obstruction. Several studies have also shown that morbidly obese subjects, independent of a diagnosis of OSA, run a higher perioperative risk of adverse airway events, including hypoxia. Providing anesthesia for this patient population is challenging and requires careful titration of drugs and superb airway management skills.

The current standard of care for oxygen delivery in this setting is a Salter nasal cannula. Humidified high flow nasal cannula (HFNC) oxygen therapy utilizes an air oxygen blend allowing from 21% to 100% FiO2 delivery and generates up to 60 L/min flow rates. The gas is heated (35 to 40 degree Celsius) and humidified through an active heated humidifier and delivered via a single limb heated inspiratory circuit (to avoid heat loss and condensation) to the subject through a large diameter nasal cannula. Theoretically, HFNC offers significant advantages in oxygenation and ventilation over conventional methods. Constant high flow oxygen delivery provides steady inspired oxygen fraction (FiO2) and decreases oxygen dilution. It also washes out physiologic dead space and generates positive end expiration pressure (PEEP) that augments ventilation.

Some studies have demonstrated a positive effect of HFNC on the apnea-hypopnea index (AHI) showing that use of HFNC could decrease hypoxic episodes in subjects with repetitive upper airway obstruction such as obstructive sleep apnea. The STOP-BANG questionnaire (SB) has been used successfully to screen patients undergoing therapeutic endoscopic procedures at higher risk for sedation-related adverse events.
Male subjects involved in races less than 60 km (H\<60) will be included. They will have neuromuscular tests in isometric mode, Transcranial Magnetic Stimulation (TMS), neuromuscular fatigue assessment test, treadmill, blood sample and urinary sample.
The proto-oncogene MYCN expression marked a cancer stem-like cell population in hepatocellular carcinoma (HCC) and served as a therapeutic target of acyclic retinoid (ACR), an orally administered vitamin A derivative that has demonstrated promising efficacy and safety in reducing HCC recurrence. This study investigated the role of MYCN as a predictive biomarker for therapeutic response to ACR and prognosis of HCC. MYCN gene expression in HCC was analyzed in the Cancer Genome Atlas and a Taiwanese cohort (N = 118). Serum MYCN protein levels were assessed in healthy controls (N = 15), patients with HCC (N = 116), pre- and post-surgical patients with HCC (N = 20), and a subset of patients from a phase 3 clinical trial of ACR (N = 68, NCT01640808). The results showed increased MYCN gene expression in HCC tumors, which positively correlated with HCC recurrence in non-cirrhotic or single-tumor patients. Serum MYCN protein levels were higher in patients with HCC, decreased after surgical resection of HCC, and were associated with liver functional reserve and fibrosis markers, as well as long-term HCC prognosis (>4 years). Subgroup analysis of a phase 3 clinical trial of ACR identified serum MYCN as the risk factor most strongly associated with HCC recurrence. Patients with HCC with higher serum MYCN levels after a 4-week treatment of ACR exhibited a significantly higher risk of recurrence (hazard ratio 3.27; p = .022). In conclusion, serum MYCN holds promise for biomarker-based precision medicine for the prevention of HCC, long-term prognosis of early-stage HCC, and identification of high-response subgroups for ACR-based treatment.
Methods, systems, and apparatus for identifying biomarkers of epileptogenesis. The repository and analytics system includes multiple data source devices. The multiple data source devices are configured to provide neurological data. The repository and analytics system includes a repository and analytics platform that is coupled to the multiple source devices. The repository and analytics platform is configured to determine a relationship or pattern within the neurological data based on a linked set of neurological data. The repository and analytics platform is configured generate a visualization that identifies biomarkers of epileptogenesis based on the relationship or pattern. The repository and analytics system includes a client device. The client device is configured to display the visualization.
Diet-based models are commonly used to investigate obesity and related disorders. We conducted a comparative profiling of three obesogenic diets HFD, high fat diet; HFHF, high fat high fructose diet; and HFCD, high fat choline deficient diet to assess their impact on the gut microbiome and metabolome. After 20 weeks, we analyzed the gut microbiota and metabolomes of liver, plasma, cecal, and fecal samples. Fecal and plasma bile acids (BAs) and fecal short-chain fatty acids (SCFAs) were also examined. Significant changes were observed in fecal and cecal metabolites, with increased Firmicutes and decreased Bacteroidetes in the HFD, HFHF, and HFCD-fed mice compared to chow and LFD (low fat diet)-fed mice. Most BAs were reduced in plasma and fecal samples of obese groups, except taurocholic acid, which increased in HFCD mice's plasma. SCFAs like acetate and butyrate significantly decreased in obesogenic diet groups, while propionic acid specifically decreased in the HFCD group. Pathway analysis revealed significant alterations in amino acid, carbohydrate metabolism, and nucleic acid biosynthesis pathways in obese mice. Surprisingly, even LFD-fed mice showed distinct changes in microbiome and metabolite profiles compared to the chow group. This study provides insights into gut microbiome dysbiosis and metabolite alterations induced by obesogenic and LFD diets in various tissues. These findings aid in selecting suitable diet models to study the role of the gut microbiome and metabolites in obesity and associated disorders, with potential implications for understanding similar pathologies in humans.
An artificial peptide having an amino acid sequence which corresponds to a naturally occurring amino acid sequence of a human parvovirus comprising an epitope and which further has two cysteine residues located on each side of said epitope, and further having a sulphur bridge between said two cysteine residues, which has been formed by a chemical oxidation step, is described.  Furthermore, an artificial antigen which reacts with antibodies induced by a human parvovirus is described. Said antigen mainly consists of an artificial peptide according to the invention. Additionally, a method of detecting antibodies induced by a human parvovirus in a sample of body fluid, wherein said sample is subjected to an immunoassay, especially ELISA, and wherein an artificial antigen according to the invention is used as a diagnostic antigen, is described. A diagnostic immunoassay kit for said method is also described. Finally, a vaccine composition comprising, as an immunizing component, at least one antigen according to the invention, is described.
A system 100 comprises a garment 11 and an electronic device 13. The garment comprises a sensor arranged to monitor the activity of a wearer of the garment and a communicator arranged to receive the activity data from the sensor and transmit the activity data. The electronic device comprises a receiver, a processor and a display unit. The receiver is arranged to receive the activity data. The processor is arranged to track the motion of the wearer of the garment and generate a representation of the received activity data. The display unit is arranged to simultaneously display a representation of the wearer and the representation of the received activity data. The representation of the activity data is displayed at a position determined based on the tracked motion of the wearer. The electronic device is further arranged to receive a user credential from a user, and the receiver only receives the activity data if the user is authorised based on the obtained user credential as having permission to access the activity data. The electronic device can transmit the credential to a server 15 so that the server determines if the user is authorised.
The invention comprises compounds of the formula <FORM:0981827/C2/1> where R represents a hydrogen atom or a methyl group, R1 represents a hydrogen atom or an alkyl radical having 1 to 4 carbon atoms and R11 represents a hydrogen atom or a radical of an aliphatic, cycloaliphatic, aromatic- or heterocyclic carboxylic acid having from 1 to 10 carbon atoms, unsubstituted or substituted by halogen atoms, free or alkylated amino, nitro, hydroxy, alkyl, alkoxy or thioether groups, and the preparation thereof by the reduction of lumilysergic acid, 1-methyl-lumilysergic acid or a corresponding 8-ester-10-ether derivative thereof, to give lumilysergol, 1-methyl-lumilysergol or the appropriate 10-ether derivative; and, where necessary, esterifying to yield the corresponding acyl derivatives.  The carboxyl group is preferably protected prior to reduction by, for example, formation of an ester or a mixed anhydride.  The reduction is carried out with a reducing agent which is capable of reducing a carboxylic group into an alcohol group, e.g. lithium aluminium hydride, in a solvent stable towards the reducing agent, e.g. an ether.  It may be carried out at room temperature but is preferably completed by warming.  The 8-acyl derivative of the lumilysergol and 1-methyl-lumilysergol so produced may be made by reaction with an acylating agent e.g. the anhydride or chloride of the appropriate carboxylic or sulphonic acid, optionally in the presence of a tertiary amine.  Lumilysergic acid and 1-methyl-lumilysergic acid may be prepared by U.V. irradiation of the corresponding lysergic acid dissolved in a dilute mineral acid.  Methylation of the 1-nitrogen atom may be carried out before or after irradiation by reaction with a methyl halide in liquid ammonia in the presence of metallic potassium.  The 8 - ester - 10 - ether derivatives of lumilysergic or 1-methyl-lumilysergic acid may be prepared from the corresponding acids by simultaneous etherification and esterification by treatment of a solution thereof in the required alcohol with anhydrous hydrogen chloride.  Therapeutic compositions with oxytocic, anti-enterammic, adrenolytic, hypotensive, and sedative activity, which may be administered orally, intramuscularly, subcutaneously and intravenously and may take the form of tablets, powders, pills or liquids, comprise compounds of the general formula given above together with a therapeutically acceptable solid or liquid vehicle therefor.
Patients receive necitumumab IV over 60 minutes and trastuzumab IV over 30-90 minutes on days 1 and 15. Patients also receive osimertinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Early thrombosis following coronary artery bypass grafting (CABG) surgery leads to perioperative myocardial infarction, which causes difficulties for clinicians and patients. Moreover, once perioperative myocardial infarction occurs, the mortality rate is extremely high. In recent years, microneedle (MN) drug delivery systems have become a research hotspot with broad clinical application prospects. These systems are capable of achieving sustained, safe, and painless local drug release. In cardiovascular applications, MNs maximize local anticoagulant effects, inhibit endometrial hyperplasia, and reduce systemic side effects. We speculate that a MN drug delivery system can be used to target transplanted veins to inhibit their thrombosis and reduce the incidence of perioperative myocardial infarction after CABG surgery. Therefore, this study developed a hyaluronic acid MN patch loaded with tirofiban and conducted preliminary physicochemical tests. The safety, efficacy, biocompatibility, and targeting of the MN system were evaluated usingin vitroandin vivoexperiments using a jugular vein transplantation model. The results indicate that the MN system has excellent physical properties, safety, effectiveness, biocompatibility, and strong targeting, which can effectively inhibit early local thrombus formation. In addition, the observation of early postoperative endometrial hyperplasia activation provides a foundation for future research.
Subject will apply the test product to all sun exposed areas of face and body, wait for 15 minutes, then sunbathe for 30 minutes, exercise for 20 minutes, and then sunbathe for additional 30 minutes. Immediately after the second sunbathing, enter the pool and remain in the water for 20 minutes. Then repeat the sun and water exposure activities again.
Patients receive fulvestrant intramuscularly (IM) on days 0, 14, and 28 of course 1 and on day 1 of all subsequent courses. Patients also receive oral placebo once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
INTRODUCTION: Acute decompensated heart failure (ADHF) is a global health problem and early detection of high-risk patients for effective treatment is important. Exhaled breath analysis and measurement of volatile organic compounds (VOCs) may be a fast and cost-effective non-invasive diagnostic and screening tool complementing measurement of cardiac biomarkers. Another technique to detect and characterize VOCs is the ion mobility spectrometry (IMS) not requiring vacuum or sample pretreatment.
METHODS: This prospective controlled proof-of-concept study prospectively enrolled adult patients with severe ADHF at the University Hospital Heart Centre Brandenburg. Severe ADHF was defined as patients presenting with symptomatic acute decompensation and NTproBNP >7000 pg/dL. Cardiac patients with NT-proBNP 220 pg/dL served as control. A gas chromatography ion mobility spectrometer (GC-IMS) of the type "MultiMarkerMonitor™" from GRAUPNER medical solutions GmbH was used. Measurement was performed at T0 (within 24 h of admission), T1 (after 3-5 days) and T2 (after 8-10 days).
RESULTS: Forty patients were enrolled in the study, 20 patients with severe ADHF and 20 control patients. In patients with severe ADHF, three clusters with significantly altered maximum peak heights were detected compared to control. There was no change in the peak height of clusters 8, 9 and 206 at the time points T1 and T2 (all p > 0.50). Also, NT-proBNP was stable over time (p = 0.247). Sixteen control patients (16/20, 80 %) and four with severe ADHF (4/20, 20 %) presented without cluster deviation. Patients with deviation in at least two clusters had longer hospital stay, 11 days (5.0-15.0) compared to those without deviation, 4 days (2.0-9.5), p = 0.028.
CONCLUSION: Longer-term follow-up studies are needed to assess the stability and clinical significance of the identified clusters by IMS and their diagnostic and prognostic relevance.
Menopause is a natural life transition experienced by half the world's population. Women aged 50 years and older are the fastest growing demographic group in many countries, making essential contributions to the workforce. Although menopause is a universal and natural life transition, the symptom experience is highly variable among women. Some women may experience few or no symptoms, whereas others may be bothered by moderate to severe symptoms for a decade or longer, which can adversely affect quality of life, relationships, job satisfaction, and career advancement. Indeed, menopause symptoms, including vasomotor and genitourinary symptoms, as well as sleep and mood disturbances are associated with multiple adverse work outcomes. Studies to date have demonstrated that these adverse work outcomes related to menopause symptoms include a compromised ability to work, reduced work productivity, absenteeism, and even loss of employment or an early exit from the workforce. Further, the relationship between menopause symptoms and work may be bidirectional, with certain aspects of the work environment being linked with a greater menopause symptom burden, such as insufficient restroom facilities, unpredictable or long work hours, the inability to take breaks, and confined or crowded workspaces. Thus, workplace solutions may need to be tailored based on women's individual needs, the work environment, and the type of work.The Menopause Society, in conjunction with an expert panel of medical and legal experts and women's health advocates, has developed a set of consensus recommendations that challenges employers to create a menopause-supportive workplace for their employees. These recommendations include, among other things, suggestions for employers to review policies and healthcare plans and benefits and to consider flexibility and accommodations that may be needed for some women with menopause symptoms. Guidance for women with menopause symptoms that affect them at work in terms of understanding their resources and empowering them to be self-advocates are also provided, as well as recommendations for what occupational health professionals should know and do for women with bothersome menopause symptoms in the workplace.